Functional connectome metrics reveal distinct prognostic subtypes in two Phase 3 gantenerumab trials.

In the whole cortex, similar differences in brain volume loss were found between Clusters 1 and 2 at both Weeks 104 and 116 (estimate cluster1‐cluster2 at w104: −0.43 ± 0.18, p = 0.04; estimate cluster1‐cluster2 at w116: −0.62 ± 0.18, p = 0.001), whereas other comparisons did not reach statistical significance (Figure 6A ). 2.10.2.

also in 111,027 other papers